Table 1_Early high-dose intravenous methylprednisolone is associated with faster symptom improvement in persistent ocular myasthenia gravis: a single-center retrospective study.docx

The mixed-effects model demonstrated a significant group-by-time interaction (p < 0.001). At 1 month, the least-squares mean ocular MG-ADL score was 0.474 (95% confidence interval [CI], 0.024–0.923) in the HMP group and 2.000 (95% CI, 1.525–2.475) in the OCS group, with a significant between-group difference after Tukey adjustment (p < 0.001). From 3 months onward, scores remained low in both groups without significant between-group differences.

The HMP group achieved minimal symptom expression earlier. Oral prednisolone doses and prednisolone-related adverse events did not differ significantly between groups. Initial worsening occurred in two HMP-treated patients, but neither developed myasthenic crisis.</p>Conclusion<p>In persistent ocular MG, early HMP as part of induction immunotherapy was associated with faster ocular symptom improvement and earlier achievement of minimal symptom expression than OCS induction alone, while long-term clinical outcomes and oral prednisolone doses were similar.

Early HMP may be useful when rapid symptom control is required, although prospective studies are needed.</p>